Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective

June 1, 2016
Supplements and Featured Publications, Cost-Effectiveness of Disease- Modifying Therapies in Multiple Sclerosis: A Managed Care Perspective, Volume 22, Issue 6 Suppl

Supplement Policy Statement

Standards for Supplements to The American Journal of Managed Care

All supplements to The American Journal of Managed Care are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All Journal supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to The American Journal of Managed Care will:

I. Be reviewed by at least one independent expert from a recognized academic medical institution.

II. Disclose the source of funding in at least one prominent place.

III. Disclose any existence of financial interests of supplement contributors to the funding organization.

IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.

V. Be up-to-date, reflecting the current (as of date of publication) standard of care.

VI. Be visually distinct from The American Journal of Managed Care.

VII. Publish information that is substantially different in form and content from that of the accompanying edition of The American Journal of Managed Care.

VIII. Prohibit excessive remuneration for contributors and reviewers.

IX. Carry no advertising.

Publisher’s Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Release date: May 12, 2016

Expiration date: May 12, 2017

Pharmacy Credit

Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information

This lesson is free online; receive instant grading and request your CE credit at

Testing and Grading Directions

1. Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest is eligible to receive CE credit.

2. Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.

3. To receive your credit online, go to, complete the online posttest (achieving a passing grade of 70% or better) and the online activity evaluation form before the expiration date. Your CE credit will be automatically uploaded to CPE MonitorTM. Please ensure your Pharmacy Times account is updated with your NABP e-profile ID number and your date of birth (MMDD format). Participation data will not be uploaded into CPE MonitorTM if you do not have your NABP e-profile ID number and date of birth entered into your profile on

Sample of Online Posttest

Choose the best answer for each of the following:

1. Approximately what percentage of cases of multiple sclerosis (MS) begin before the age of 18 years?

A. 10%

B. 15%

C. 20%

D. 25%

2. Which of the following is considered to be a putative risk factor for the development of MS?

A. Birth in March

B. High vitamin D level

C. Smoking

D. Male sex

3. Which of the following factors indicates a worse prognosis in MS?

A. Age >40 years at disease onset

B. Age <30 years at disease onset

C. Female sex

D. No cognitive impairment at disease onset

4. Relapsing-remitting MS accounts for what proportion of the initial diagnoses of MS?

A. 30% to 40%

B. 50% to 60%

C. 70% to 80%

D. 90% to 100%

5. Linda is a 43-year-old woman who was previously diagnosed with progressive-relapsing MS based on history and physical exam, along with findings from magnetic resonance imaging and erebrospinal fluid testing. Her most recent 3-month follow-up exam demonstrated the occurrence of contrast-enhancing T1 hyperintense lesions and disability without unequivocal recovery. Based on the 2013 MS phenotype descriptions, Linda would be classified as having:

A. Clinically isolated syndrome

B. Primary-progressive MS

C. Secondary-progressive MS

D. Progressive-relapsing MS

6. The lifetime prevalence of depression in patients with MS may be as high as:

A. 25%

B. 50%

C. 75%

D. 100%

7. Results from a longitudinal study evaluating sexual function found that:

A. Sexual dysfunction affected predominantly men with MS.

B. Sexual dysfunction affected predominantly women with MS.

C. Sexual dysfunction decreased after initial diagnosis in both men and women with MS.

D. The risk of sexual dysfunction increased over time in both men and women with MS.

8. On average, how many visits to healthcare providers does an individual newly diagnosed with MS make per year?

A. 4

B. 8

C. 12

D. 16

9. All of the following are true about catastrophic limits in healthcare insurance coverage, EXCEPT:

A. This term refers to the maximum amount of particular covered charges set by a healthcare plan to be paid out-of-pocket by a beneficiary annually.

B. Catastrophic limits define the amount an insured patient must pay before the insurer pays the healthcare bills.

C. Medicare requires enrollees to pay an additional 10% of some specialty drug costs even after the catastrophic limit has been reached.

D. Catastrophic limits may vary among different insurance plans.

10. Charges/costs for MS were found to be significantly higher for patients with which of the common disease sequelae/comorbidities associated with MS?

A. Fatigue/malaise

B. Depression

C. Paresthesia

D. All of the above

11. In 2011, approximately what percentage of total MS-related healthcare costs were attributed to monotherapy with a disease-modifying therapy?

A. 25%

B. 50%

C. 75%

D. >90%

12. All of the following statements are true about the management of MS relapses, EXCEPT:

A. Intravenous immunoglobulin is an option for pregnant women experiencing relapses.

B. Plasmapheresis is first-line treatment for patients experiencing severe relapses.

C. Short-term courses of high-dose corticosteroids are an established practice to treat acute exacerbations.

D. Treatment with steroids has been found to reduce symptoms, improve motor function, and shorten time to recovery from acute attacks.

13. Which of the following DMTs carries a Pregnancy Category X designation?





14. Which of the following DMTs has a black box warning for progressive multifocal leukoencephalopathy?

A. Alemtuzumab

B. Mitoxantrone

C. Natalizumab

D. Ocrelizumab

15. All of the following statements are true with regard to treatment adherence, EXCEPT:

A. Adherence to therapy is not necessary for effective disease management.

B. Patients who adhere to a DMT regimen use fewer medical resources and have lower diseaserelated medical costs.

C. Patients with MS who have high out-of-pocket costs are more likely to forgo treatment or stop therapy prematurely than others who have lower out-of-pocket expenses.

D. Real or perceived lack of efficacy, adverse effects, and needle phobia can be barriers to adherence.